Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis

M. L. Steinhauser, C. M. Hogaboam, Akihiro Matsukawa, N. W. Lukacs, R. M. Strieter, S. L. Kunkel

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Previous studies have suggested that the C-C chemokine C10 is involved in the chronic stages of host defense reactions. The present study addressed the role of C10 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Unlike other C-C chemokines, C10 levels in the peritoneal wash were increased approximately 30-fold above baseline levels at 48 h after CLP surgery. Immunoneutralization of peritoneal C10 levels with polyclonal anti-C10 antiserum during CLP-induced peritonitis negatively impacted mouse survival over 4 days. In contrast, when 500 ng of recombinant murine C10 was administered immediately after CLP surgery, the 4-day survival rate increased from 20% to over 60%. The C10 therapy appeared to facilitate a rapid and significant enhancement of the levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattracrant protein-1 (MCP-1) and a later increase in interieukin-13 (IL-13) levels in the peritoneal cavity. In vitro studies showed that the combination of IL-1β and C10 markedly augmented TNF-α synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13. At 24 h after CLP surgery, only 25% of C10-treated mice were bacteremic versus 85% of the control group that exhibited dissemination of bacteria into the circulation. The lack of bacteremia in C10-treated mice appeared to be related, in part, to in vitro evidence flint C10 significantly enhanced the bacterial phagocytic activity of peritoneal macrophages. In addition, in vivo evidence suggested that C10 therapy significanfly reduced the amount of material that leaked from the damaged gut. Taken together, the results of this study demonstrate that the C10 chemokine rapidly promotes disease resolution in the CLP model through its direct effects on the cellular events critically involved in host defense during septic peritonitis.

Original languageEnglish
Pages (from-to)6108-6114
Number of pages7
JournalInfection and Immunity
Volume68
Issue number11
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Punctures
Chemokines
Ligation
Sepsis
Theoretical Models
Peritonitis
CC Chemokines
Interleukin-13
Peritoneal Macrophages
Tumor Necrosis Factor-alpha
Peritoneal Cavity
Bacteremia
Ambulatory Surgical Procedures
Interleukin-1
Immune Sera
Monocytes
Bacteria
Control Groups
Therapeutics
Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. / Steinhauser, M. L.; Hogaboam, C. M.; Matsukawa, Akihiro; Lukacs, N. W.; Strieter, R. M.; Kunkel, S. L.

In: Infection and Immunity, Vol. 68, No. 11, 2000, p. 6108-6114.

Research output: Contribution to journalArticle

Steinhauser, M. L. ; Hogaboam, C. M. ; Matsukawa, Akihiro ; Lukacs, N. W. ; Strieter, R. M. ; Kunkel, S. L. / Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. In: Infection and Immunity. 2000 ; Vol. 68, No. 11. pp. 6108-6114.
@article{54e881653a634ea4aa0cd4d2e3bb2457,
title = "Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis",
abstract = "Previous studies have suggested that the C-C chemokine C10 is involved in the chronic stages of host defense reactions. The present study addressed the role of C10 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Unlike other C-C chemokines, C10 levels in the peritoneal wash were increased approximately 30-fold above baseline levels at 48 h after CLP surgery. Immunoneutralization of peritoneal C10 levels with polyclonal anti-C10 antiserum during CLP-induced peritonitis negatively impacted mouse survival over 4 days. In contrast, when 500 ng of recombinant murine C10 was administered immediately after CLP surgery, the 4-day survival rate increased from 20{\%} to over 60{\%}. The C10 therapy appeared to facilitate a rapid and significant enhancement of the levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattracrant protein-1 (MCP-1) and a later increase in interieukin-13 (IL-13) levels in the peritoneal cavity. In vitro studies showed that the combination of IL-1β and C10 markedly augmented TNF-α synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13. At 24 h after CLP surgery, only 25{\%} of C10-treated mice were bacteremic versus 85{\%} of the control group that exhibited dissemination of bacteria into the circulation. The lack of bacteremia in C10-treated mice appeared to be related, in part, to in vitro evidence flint C10 significantly enhanced the bacterial phagocytic activity of peritoneal macrophages. In addition, in vivo evidence suggested that C10 therapy significanfly reduced the amount of material that leaked from the damaged gut. Taken together, the results of this study demonstrate that the C10 chemokine rapidly promotes disease resolution in the CLP model through its direct effects on the cellular events critically involved in host defense during septic peritonitis.",
author = "Steinhauser, {M. L.} and Hogaboam, {C. M.} and Akihiro Matsukawa and Lukacs, {N. W.} and Strieter, {R. M.} and Kunkel, {S. L.}",
year = "2000",
doi = "10.1128/IAI.68.11.6108-6114.2000",
language = "English",
volume = "68",
pages = "6108--6114",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis

AU - Steinhauser, M. L.

AU - Hogaboam, C. M.

AU - Matsukawa, Akihiro

AU - Lukacs, N. W.

AU - Strieter, R. M.

AU - Kunkel, S. L.

PY - 2000

Y1 - 2000

N2 - Previous studies have suggested that the C-C chemokine C10 is involved in the chronic stages of host defense reactions. The present study addressed the role of C10 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Unlike other C-C chemokines, C10 levels in the peritoneal wash were increased approximately 30-fold above baseline levels at 48 h after CLP surgery. Immunoneutralization of peritoneal C10 levels with polyclonal anti-C10 antiserum during CLP-induced peritonitis negatively impacted mouse survival over 4 days. In contrast, when 500 ng of recombinant murine C10 was administered immediately after CLP surgery, the 4-day survival rate increased from 20% to over 60%. The C10 therapy appeared to facilitate a rapid and significant enhancement of the levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattracrant protein-1 (MCP-1) and a later increase in interieukin-13 (IL-13) levels in the peritoneal cavity. In vitro studies showed that the combination of IL-1β and C10 markedly augmented TNF-α synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13. At 24 h after CLP surgery, only 25% of C10-treated mice were bacteremic versus 85% of the control group that exhibited dissemination of bacteria into the circulation. The lack of bacteremia in C10-treated mice appeared to be related, in part, to in vitro evidence flint C10 significantly enhanced the bacterial phagocytic activity of peritoneal macrophages. In addition, in vivo evidence suggested that C10 therapy significanfly reduced the amount of material that leaked from the damaged gut. Taken together, the results of this study demonstrate that the C10 chemokine rapidly promotes disease resolution in the CLP model through its direct effects on the cellular events critically involved in host defense during septic peritonitis.

AB - Previous studies have suggested that the C-C chemokine C10 is involved in the chronic stages of host defense reactions. The present study addressed the role of C10 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Unlike other C-C chemokines, C10 levels in the peritoneal wash were increased approximately 30-fold above baseline levels at 48 h after CLP surgery. Immunoneutralization of peritoneal C10 levels with polyclonal anti-C10 antiserum during CLP-induced peritonitis negatively impacted mouse survival over 4 days. In contrast, when 500 ng of recombinant murine C10 was administered immediately after CLP surgery, the 4-day survival rate increased from 20% to over 60%. The C10 therapy appeared to facilitate a rapid and significant enhancement of the levels of tumor necrosis factor alpha (TNF-α) and monocyte chemoattracrant protein-1 (MCP-1) and a later increase in interieukin-13 (IL-13) levels in the peritoneal cavity. In vitro studies showed that the combination of IL-1β and C10 markedly augmented TNF-α synthesis by peritoneal macrophages and that C10 synthesis was induced in these cells following their exposure to IL-13. At 24 h after CLP surgery, only 25% of C10-treated mice were bacteremic versus 85% of the control group that exhibited dissemination of bacteria into the circulation. The lack of bacteremia in C10-treated mice appeared to be related, in part, to in vitro evidence flint C10 significantly enhanced the bacterial phagocytic activity of peritoneal macrophages. In addition, in vivo evidence suggested that C10 therapy significanfly reduced the amount of material that leaked from the damaged gut. Taken together, the results of this study demonstrate that the C10 chemokine rapidly promotes disease resolution in the CLP model through its direct effects on the cellular events critically involved in host defense during septic peritonitis.

UR - http://www.scopus.com/inward/record.url?scp=0033784259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033784259&partnerID=8YFLogxK

U2 - 10.1128/IAI.68.11.6108-6114.2000

DO - 10.1128/IAI.68.11.6108-6114.2000

M3 - Article

C2 - 11035713

AN - SCOPUS:0033784259

VL - 68

SP - 6108

EP - 6114

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 11

ER -